← Patent-cliff monitor Loss of exclusivity November 2034 latest FDA-listed patent expiry
Drug detail Brand name SYNJARDY Active ingredient EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE Strength 12.5MG;500MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval August 2015 Marketing status RX
Listed patents Patent Expires Type 9949997*PED November 2034 — 11090323*PED October 2034 — 11833166*PED October 2034 — 12433906*PED October 2034 — 10258637*PED October 2034 — 9949997 May 2034 use U-3533 11090323 April 2034 use U-3193 10258637 April 2034 use U-2290 12433906 April 2034 use U-4296 11666590 April 2034 use U-4154 12263153 April 2034 use U-4154 12427162 April 2034 use U-4287 11833166 April 2034 use U-3776 12527810*PED October 2033 — 12527810 April 2033 use U-4403 10610489*PED March 2031 — 10610489 September 2030 product 12115179*PED August 2030 — 12115179 February 2030 use U-4023 7579449*PED February 2029 — 7579449 August 2028 substance 7713938*PED October 2027 — 7713938 April 2027 substance, product
Regulatory exclusivity Code Expires PED December 2026 NPP June 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.